Scilex Holding Co

SCLX · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances)
195
SEC Filings

Business Summary

PART I . The Company We are an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. We target indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Our commercial products are: (i) ZTlido (lidocaine topical system) 1.8%, a ...

Next Earnings

Q2 FY2026 — expected 2026-09-26

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionSCLXdiscussed_in_filing Cybersecurity
topic_mentionSCLXdiscussed_in_filing Cybersecurity

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2025-03-312024-12-310000950170-25-047800EDGAR160K words
2024-03-122023-12-310000950170-24-029473EDGAR—
2023-03-072022-12-310000950170-23-006493EDGAR—
2022-02-242021-12-310001213900-22-009229EDGAR—
2021-03-312020-12-310001213900-21-019230EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-142025-09-300001193125-25-283153EDGAR74K words
2025-08-132025-06-300000950170-25-108029EDGAR—
2025-05-142025-03-310000950170-25-071517EDGAR—
2025-01-172024-09-300000950170-25-006755EDGAR—
2024-08-132024-06-300000950170-24-096199EDGAR—
2024-05-132024-03-310000950170-24-058630EDGAR—
2023-11-142023-09-300000950170-23-063810EDGAR—
2023-08-112023-06-300000950170-23-041842EDGAR—
2023-05-122023-03-310000950170-23-021743EDGAR—
2022-11-042022-09-300001213900-22-069366EDGAR—
2022-08-122022-06-300001213900-22-047404EDGAR—
2022-05-162022-03-310001213900-22-027064EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-130001193125-26-105675EDGAR1K words
2026-03-130001193125-26-104940EDGAR—
2026-02-200001193125-26-061371EDGAR—
2026-02-030001193125-26-035833EDGAR—
2026-02-020001193125-26-033620EDGAR—
2025-12-300001193125-25-336947EDGAR—
2025-12-220001193125-25-328656EDGAR—
2025-12-170001193125-25-321928EDGAR—
2025-12-120001193125-25-317587EDGAR—
2025-12-110001193125-25-316239EDGAR—

195 total filings indexed. 168 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Company Identity

CIK0001820190
TickerSCLX
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 1333f3a8f688e4cb8d9d905e27ff17dc37c5cd2fa1511fb3158939415369521b
parent: 5cd8167efe19a8ffea8bba1c4b7906c1229ca48b6025052cb3ae174bc4ede930
content hash: 50195eaa22d492a8f3ceef908f182c8bca88fbaa0bf579c7a7d8c377807140ae
signed: 2026-04-13T04:47:21.140Z
sources: 17 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf